Rejuvenation Roundup February 2026
The roundup covers clinical, preclinical, and lifestyle advances across geroscience. The FDA cleared Life Biosciences' first human cellular reprogramming trial for two age-related vision diseases. Multiple studies report modulators of biological aging, including a 15,000+ participant vitamin analysis (vitamins C and B2), sleep-linked myelin loss reversible via cholesterol homeostasis, metabolic drivers of adipose stem cell dysfunction (Cell Discovery), exercise and supplementation benefits for brain and muscle, and short-term rapamycin effects on reproductive and somatic stem cells; a phase 2b stem cell trial tested laromestrocel for frailty. Major translation-focused meetings convened at the National University of Singapore and a Longevity Innovation Forum in San Diego.
Why it mattersFDA cleared Life Biosciences' reprogramming trial; monitor its vision-disease endpoints to guide investment and regulatory strategy.